Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages 721-726

  Lehman, Vance T ^a   Carter, Rickey E ^a   Claassen, Daniel O ^b   Murphy, Robert C ^a   Lowe, Val ^a   Petersen, Ronald C ^a   Peller, Patrick J ^a  

^a MAYO CLINIC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

3D SSP; Alzheimer disease; brain PET; mild cognitive impairment; PET; stereotactic surface display; three dimensional

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STEREOTACTIC PROCEDURE; THREE DIMENSIONAL IMAGING; THREE DIMENSIONAL STEREOTACTIC SURFACE PROJECTION;

AGED; ALZHEIMER DISEASE; DEMOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; ROC CURVE; STEREOTAXIC TECHNIQUES;

EID: 84863864346     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182478d89     Document Type: Article

References (20)

1. Alzheimer's Association: Alzheimer's Association report 2011 Alzheimer's Disease Facts and Figures. Alzheimers Dement. 2011;7:208-244.
2. Mosconi L, Tsui WH, Herholz k, et al. Multicenter standardization of F-18 FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398. (Pubitemid 351355204)
3. Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-877. (Pubitemid 47329586)
4. De leon MJ, Convit A,Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl ACD Sci USA. 2001;98:10966-10971.
5. Jagust W, Gitcho A, Sun F, et al. Brain imaging evidence of preclinical Alzheimer's Disease in normal aging. Ann Neurol. 2006;59:673-681.
6. Burdette JH, Minoshima S, Vander Borght T, et al. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotactic surface projections. Radiology. 1996;198:837-843. (Pubitemid 26066307)
7. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage. 2002;17:302-316.
8. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616-2635. (Pubitemid 47511706)
9. Ishii K, Kono AK, Sasaki H, et al. Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2006;33:575-583.
10. Morbelli S, Piccardo A, Villavecchia G, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36-45.
11. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging. 2012;33:198.e1-14.
12. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology. 2007;68:501-508.
13. Monsch AU, Bondi MW, Salmon DP, et al. Clinical validity of the mattis dementia rating scale in detecting dementia of the Alzheimer type: a double cross-validation and application to a community-dwelling sample. Arch Neuro. 1995;52:899-904.
14. Pedraza O, Lucas JA, Smith GE, et al. Robust and expanded norms for the dementia rating scale. Arch Clin Neuropsychol. 2010;25:347-358.
15. Minoshima S, Frey KA, Koeppe RA. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine- 18-FDG PET. J Nucl Med. 1995;36:1238-1248.
16. Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for reporting of diagnostic accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326:41-44. (Pubitemid 36110721)
17. Foster NL. Barriers to treatment: the unique challenges for physicians providing dementia care. J Geriatr Psychiatry Neurol. 2001;14:188-198. (Pubitemid 33108170)
18. Duara R, Barker W, Loewenstein D, et al. The basis for disease-modifying treatments for Alzheimer's disease: the sixth annual mild cognitive impairment symposium. Alzheimers Dement. 2009;5:66-74.
19. Burns A, Lliffe S. Alzheimer disease. BMJ. 2009;338:b158.
20. Jean L, Bergeron M, Thivierge S, et al. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry. 2010;18:281-296.